Literature DB >> 25825336

Effect of Membrane Permeability on Cardiovascular Risk Factors and β2m Plasma Levels in Patients on Long-Term Haemodialysis: A Randomised Crossover Trial.

Charles Chazot1, Judith Kirchgessner, Jenny Pham, Cyril Vo-Van, Christie Lorriaux, Jean-Marc Hurot, Eric Zaoui, Aileen Grassmann, Guillaume Jean, Daniele Marcelli.   

Abstract

Survival of haemodialysis (HD) patients is influenced by many factors. Mortality is mainly of cardiovascular (CV) origin and related to both traditional and nontraditional CV risk factors. Low plasma Beta2-microglobulin (β2m) levels are associated with improved HD patient survival. HD session times that are longer than the conventional 4 h (i.e., extended dialysis) provide better middle molecule clearance and are also associated with a survival advantage. In this crossover randomised trial, we investigated the effect of membrane flux on CV risk factors and on β2m plasma levels in patients treated with extended dialysis. Dialysis session duration was between 5 and 8 h for all patients. Patients were randomly assigned to the treatment sequences low-flux/high-flux dialysis versus high-flux/low-flux dialysis in a crossover design after a 3-month run-in period, with each phase lasting 9 months. Of the initially enrolled 168 patients, 155 patients started the study after the run-in period, 117 patients completed Phase 1, and 83 patients completed the whole study. Lp(a), homocystein, LDL cholesterol, HDL cholesterol and serum albumin were comparable in the low-flux and high-flux treatments. The average β2m level was 43.3 ± 11.1 mg/l at the end of the low-flux phase. Independent of sequence assignation, average β2m was significantly lower at the end of the high-flux phase (27.5 ± 76.0 mg/l, p < 0.0001 versus end of low-flux phase). Both phosphate and nPNA were significantly lower at the end of the high-flux phase compared to the low-flux phase (p = 0.045 and p = 0.002, respectively). Inclusion of those patients who completed Phase 1 and who dropped out of the study during Phase 2 did not significantly change the results. In conclusion, this study did not find an influence of high-flux filters on several traditional CV risk factors in a population of HD patients treated with extended dialysis. However, high-flux filters are necessary to optimise middle molecule clearance and reduce the β2m level.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25825336     DOI: 10.1159/000380767

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  6 in total

Review 1.  Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases.

Authors:  Christos P Argyropoulos; Shan Shan Chen; Yue-Harn Ng; Maria-Eleni Roumelioti; Kamran Shaffi; Pooja P Singh; Antonios H Tzamaloukas
Journal:  Front Med (Lausanne)       Date:  2017-06-15

2.  Clinical Interventions and All-Cause Mortality of Patients with Chronic Kidney Disease: An Umbrella Systematic Review of Meta-Analyses.

Authors:  Jong Yeob Kim; Johanna Steingroever; Keum Hwa Lee; Jun Oh; Min Jae Choi; Jiwon Lee; Nicholas G Larkins; Franz Schaefer; Sung Hwi Hong; Gwang Hun Jeong; Jae Il Shin; Andreas Kronbichler
Journal:  J Clin Med       Date:  2020-02-01       Impact factor: 4.241

3.  Executive Summary of the Korean Society of Nephrology 2021 Clinical Practice Guideline for Optimal Hemodialysis Treatment.

Authors:  Ji Yong Jung; Kyung Don Yoo; Eunjeong Kang; Hee Gyung Kang; Su Hyun Kim; Hyoungnae Kim; Hyo Jin Kim; Tae-Jin Park; Sang Heon Suh; Jong Cheol Jeong; Ji-Young Choi; Young-Hwan Hwang; Miyoung Choi; Yae Lim Kim; Kook-Hwan Oh
Journal:  Kidney Res Clin Pract       Date:  2021-12-10

4.  Korean Society of Nephrology 2021 Clinical Practice Guideline for Optimal Hemodialysis Treatment.

Authors:  Ji Yong Jung; Kyung Don Yoo; Eunjeong Kang; Hee Gyung Kang; Su Hyun Kim; Hyoungnae Kim; Hyo Jin Kim; Tae-Jin Park; Sang Heon Suh; Jong Cheol Jeong; Ji-Young Choi; Young-Hwan Hwang; Miyoung Choi; Yae Lim Kim; Kook-Hwan Oh
Journal:  Kidney Res Clin Pract       Date:  2021-12-10

Review 5.  Executive summary of the Korean Society of Nephrology 2021 clinical practice guideline for optimal hemodialysis treatment.

Authors:  Ji Yong Jung; Kyung Don Yoo; Eunjeong Kang; Hee Gyung Kang; Su Hyun Kim; Hyoungnae Kim; Hyo Jin Kim; Tae-Jin Park; Sang Heon Suh; Jong Cheol Jeong; Ji-Young Choi; Young-Hwan Hwang; Miyoung Choi; Yae Lim Kim; Kook-Hwan Oh
Journal:  Korean J Intern Med       Date:  2022-06-03       Impact factor: 3.165

6.  Effect of changing treatment to high-flux hemodialysis (HFHD) on mortality in patients with long-term low flux hemodialysis (LFHD): a propensity score matched cohort study.

Authors:  Shuxin Liu; Hong Liu; Zhihong Wang; Lanbo Teng; Cui Dong; Tingting Gui; Yu Zhang
Journal:  BMC Nephrol       Date:  2020-11-16       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.